Vertex Pharmaceuticals Inc. VRTX
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · vrtx.com
Vertex Pharmaceuticals Incorporated is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases. The company is a leader in cystic fibrosis treatment with approved therapies including TRIKAFTA/KAFTRIO, and is headquartered in Boston, Massachusetts.
Key ratios
FreeCashFlowOnSale TTM 0.27
FreeCashFlowOnSale 2025 0.27
FreeCashFlowOnSale 2024 -0.07
FreeCashFlowOnSale 2023 0.34
NetIncomeMargin TTM 0.33
NetIncomeMargin 2025 0.33
NetIncomeMargin 2024 -0.05
NetIncomeMargin 2023 0.37
ReturnOnAssets TTM 0.12
ReturnOnAssets 2025 0.12
ReturnOnAssets 2024 0.12
ReturnOnAssets 2023 0.13
ReturnOnEquity TTM 0.23
ReturnOnEquity 2025 0.23
ReturnOnEquity 2024 -0.03
ReturnOnEquity 2023 0.23
Recent news
Vertex Signs Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for ALYFTREK for the Treatment of Cystic Fibrosis
2026-07-06 · Newswire (CNW)
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
2026-06-11 · BioSpace / Vertex Pharmaceuticals
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
2026-06-01 · Vertex Pharmaceuticals Newsroom